1450 ET - CVS Health faces strong pushback from patients on its pharmacy-benefit manager's move to favor the weight-loss medication Wegovy over its rival Zepbound starting next month, UBS analysts say in a research note. Their checks of social media channels showed very high patient awareness of the upcoming changes, which would automatically give prior authorizations for Wegovy to anyone with a prior authorization for Zepbound. Appeals of this change can be made, but pricing remains unknown for successful appeals, the analysts say. Patient pushback is high; some have started a petition and have been contacting the government and employer HR departments to maintain Zepbound access, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
June 10, 2025 14:50 ET (18:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。